ArticleNeurology(R) neuroimmunology & neuroinflammation2025
Elevated ITGAX/CD11c in CSF-Derived Extracellular Vesicles Reflects Disability Progression in Multiple Sclerosis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The New Spine of Access to the Brain's Secrets: Extracellular Vesicles from Cerebrospinal Fluid Liquid Biopsies in CNS Diseases and Blood-Brain Barrier Research.Molecular neurobiology · 2026Review
- Identification of diagnostic biomarkers for relapsing-remitting multiple sclerosis in plasma by mass spectrometry-based proteomics.Journal of neuropathology and experimental neurology · 2026Article
- Integrated transcriptomics and single-cell analysis identify ITGAX⁺ macrophages as key immunosuppressive factors in the prostate cancer tumor microenvironment.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesExtracellular vesicles (EVs) are membrane-bound particles that are released into the extracellular space and are believed to play a role in the pathogenesis of neuroinflammation and neurodegeneration. Nevertheless, the precise role of these vesicles in the context of multiple sclerosis (MS) remains uncertain. The objective of this study was to identify the distinctive characteristics of EVs associated with MS.
methodsEVs were isolated from CSF using phosphatidylserine affinity methods. Mass spectrometry was used to analyze CSF samples and EVs isolated from those CSF samples collected from a discovery cohort of 10 patients with other neurologic diseases (ONDs) and 10 patients with MS. In addition, mass spectrometry was used to analyze EVs isolated from CSF samples in a validation cohort of 24 patients with ONDs, 38 patients with MS, and 14 patients with neuromyelitis optica spectrum disorders.
resultsThe results revealed notable increases in the levels of 33 proteins in the CSF samples and 100 proteins in the CSF-derived EVs from patients with MS in the validation cohort. Increases in the levels of ITGA4, ITGAX (CD11c), MS4A1 (CD20), CD3E, CD4, and CD8A, which are marker proteins of lymphocytes and myeloid cells, including activated microglia and dendritic cells, were observed in the CSF-derived EVs in the discovery cohort. The results of the validation cohort revealed that the levels of 4 proteins, ITGA4, ITGAX, MS4A1, and CD3E, were significantly greater in patients with MS than in patients with ONDs. Furthermore, the level of ITGAX was greater in the patients with confirmed disability worsening (CDW) than in those without CDW. The results of the receiver operating characteristic (ROC) and Kaplan-Meier analyses indicated that ITGAX levels in CSF-derived EVs may prove useful in predicting disease prognosis. DISCUSSION: Our findings suggest that CSF-derived EVs reflect immunologic changes in MS and other neuroimmune diseases. In addition, these results raise the possibility that changing in myeloid cells and lymphocytes may also play a role in the pathogenesis of MS. CSF-derived EVs may serve as indicators of MS disease severity and could be used as biomarkers in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.